AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer
May 21 2020 - 8:30AM
Business Wire
AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a
biotechnology company developing therapeutics for human aging and
regeneration, announced today that Andrea Park has been appointed
Chief Financial Officer. Ms. Park replaces Russell Skibsted who
served in that role since the Company was organized in 2017.
Andrea Park served as our Vice President of Finance and
Controller since October 2019. Her career includes over 24 years of
public accounting and finance experience. Before joining AgeX, she
served as Vice President of Finance and Controller of Lineage Cell
Therapeutics, Inc. While at Lineage from August 2009 to September
2019, Ms. Park was directly involved in the accounting and
financial reporting of the public spin-off and eventually the
deconsolidation of three of its then subsidiaries including
Asterias Biotherapeutics, Inc., OncoCyte Corporation and AgeX.
Earlier in her career she has worked in the audit and assurance
practice at Deloitte. Ms. Park has a B.A. in Business Economics
with Concentration in Accounting from the University of California,
Santa Barbara.
Mr. Skibsted will continue to provide services to the company as
a consultant.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a variety of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s delivery
technology to stably engraft PureStem cell therapies in the body.
AgeX’s core product pipeline is intended to extend human
healthspan. AgeX is seeking opportunities to establish licensing
and collaboration arrangements around its broad IP estate and
proprietary technology platforms and therapy product
candidates.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of
AgeX’s most recent Annual Report on Form 10-K and Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commissions
(copies of which may be obtained at www.sec.gov). Subsequent events
and developments may cause these forward-looking statements to
change. AgeX specifically disclaims any obligation or intention to
update or revise these forward-looking statements as a result of
changed events or circumstances that occur after the date of this
release, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200521005241/en/
Michael D. West, Ph.D. mwest@agexinc.com (510) 671-8370
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Apr 2023 to Apr 2024